Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis.
Asli KöskdereliogluMuhtesem GedizliogluNeslihan EskutPinar TamerGizem YalcinGiray BozkayaPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
In this study, we aimed to determine serum chemerin levels in patients with MS. However, in our study, there was no significant difference between serum chemerin levels of MS patients and healthy controls'. Additionally, chemerin levels were not associated with other metabolic parameters, as well as cognitive dysfunction. Further studies are needed to evaluate the role of chemerin in MS patients.